Message from the President   Corporate Philosophy   History   Financial Highlights   Presentations & Results   Annual Report   Overseas Network   Main Products   Research & Development   Production   Sales   Publicity   Social Programs   Contact us   Disclaimer	» 2010.08.27 Conduct ofAdditional Clinical Study of KW-2246, a Cancer Pain Drug » 2010.08.11 Noven Pharmaceuticals, Inc. press release : Noven to acquire Daytrana® methylphenidate transdermal system from Shire » 2010.06.30 FY02/2011 Q1 Results Earnings Release Presentation » 2010.06.14 Financial Support to SAGA Heavy Ion Medical Accelerator in Tosu Project » 2010.06.11 Announcement of Listing of "FENTOS® TAPE," a transdermal, long-acting cancer pain relief patch, on the NHI Drug Price Standard » 2010.05.26 Notice of Application for Delisting of Stock on Osaka Stock Exchange » 2010.05.26 Notice of Personnel Changes » 2010.04.23 Results of Phase III Clinical Trial of HKT-500 in the USA » 2010.04.16 Hisamitsu Pharmaceutical Announces Marketing Approval of FENTOS® TAPE (Development Code: HFT-290), Transdermal, Long-Acting Cancer Pain Relief Patch » 2010.04.08 FY02/2010 Q4 Results Earnings Release Presentation » 2010.03.25 Hisamitsu Announces U.S. Launch of its "Fentanyl Transdermal System" for the Management of Chronic Pain » 2010.03.24 Revision of Earnings Forecast » 2010.02.25 Application Filed for Cancer Pain Drug (KW-2246) » 2010.02.01 Kyowa Hakko Kirin and Hisamitsu entered into a Joint Distribution Agreement on Cancer Pain Drug (Development Code: KW-2246) » 2010.01.08 FY02/2010 Q3 Results Earnings Release Presentation » 2009.12.11 Notice concerning acquisition result and acquisition end of company�fs own shares. (Acquisition of company�fs own shares under the regulations of the articles of association in accordance to paragraph 2, article 165 of the corporation law) » 2009.12.03 Investment in Kind to our Subsidiary in the US » 2009.11.12 Notice concerning the decision of matters relating to acquisition of company's own shares. (Acquisition of company's own shares under the regulations of the articles of association in accordance to paragraph 2, article 165 of the corporation law) » 2009.11.09 Additional Indication (For relief of local pain associated with rheumatoid arthritis) Approved for "MOHRUS Tape," a topical analgesic and anti-inflammatory product (Development Code: KPT-220) » 2009.10.19 Hisamitsu Announces FDA Approval of its Fentanyl Transdermal System for Management of Chronic Pain (Development code: HFG-512) » 2009.09.30 FY02/2010 Q2 Results Earnings Release Presentation » 2009.08.28 Completion of the tender offer for acquisition of shares of Noven Pharmaceuticals, Inc. by our subsidiary » 2009.08.25 Results of a Phase II clinical study of HTU-520 (terbinafine hydrochloride, patch), atherapeutic agent for tinea unguium » 2009.08.21 Results of tender offer for acquisition of Noven Pharmaceuticals, Inc. by our subsidiary » 2009.08.06 Phase II study results of HOB-294 (transdermal oxybutynin hydrochloride) for treatment of overactive bladder » 2009.07.27 The 4th Medium Term Management Plan » 2009.07.27 4th Medium-term Management Objectives » 2009.07.14 Acquisition of Noven Pharmaceuticals,Inc. » 2009.07.14 Hisamitsu to Acquire US-based Noven Pharmaceuticals Inc. » 2009.06.30 FY02/2010 Q1 Results Earnings Release Presentation » 2009.04.07 FY02/2009 Q4 Results Earnings Release Presentation » 2009.03.24 Modification of Earnings Forecast » 2009.03.18 Notice concerning acquisition result and acquisition end of company's own shares. Past news »